Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2005
06/02/2005US20050119338 Combination of cytochome p450 dependent protease inhibitors
06/02/2005US20050119334 Neurodegenerative disease; Alzheimer's and Parkinson's disease
06/02/2005US20050119333 Compositions comprising ether compounds and pharmaceutical uses therefor
06/02/2005US20050119323 Hormone sensitive vcancer; antiproliferative agents ; induction apoptosis; angiotensin inhibitors
06/02/2005US20050119321 2-substituted-1,3-thiazole compounds
06/02/2005US20050119320 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
06/02/2005US20050119316 Semicarbazide derivatives and the use thereof as antithrombotics
06/02/2005US20050119305 N-hydroxy-6-[(4-phenylbenzoyl)amino]hexanamide; hydroxamic acid derivative and equivalent thereof; antiinflammatory, anticarcinogenic, antiarthritic, antidiabetic agents; sepsis, leukemia, osteoporosis, skin disorders, cachexia, autoimmune diseases, hepatitis, endometriosis; hypergammaglobulinemia
06/02/2005US20050119304 N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(1H-indazol-5-yl)urea; vanilloid receptor (VR1) antagonist; blockage of neurotransmitter release
06/02/2005US20050119303 kit; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; VEGF (endothelial growth factor)and FGF (fibroblast growth factor) receptor kinase inhibitors or antibody; integrin inhibitor; synergistic
06/02/2005US20050119297 Use of 5HT3 agonists for relaxing the fundus
06/02/2005US20050119290 N-(2-[N',N'-diethylamino]-5-[N''-(4-fluorophenylsulfonyl)-N''-propargylamino]pyrimidin-4-yl)-4'-(pyrrolidin-1-ylcarbonyloxy)-L-phenylalanine; antiinflammatory, antiarthritic agents
06/02/2005US20050119271 Pyrimidine A2B selective antagonist compounds, their synthesis and use
06/02/2005US20050119267 Diazabicyclo alkane derivatives with nk1 antagonistic activity
06/02/2005US20050119263 Synergistic mixture of n,n-diethyl, (2-(4-phenylnethyl)phenoxy) ethanamine and adriamycin
06/02/2005US20050119259 Synergistic mixture of anticoagulant and antiarrhythmia agents
06/02/2005US20050119257 Cyclic sulfone containing retroviral protease inhibitors
06/02/2005US20050119256 Aromatic amino acid derivates and medicinal compositions
06/02/2005US20050119255 Phenylpyrimidine amines as ige inhibitors
06/02/2005US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase
06/02/2005US20050119246 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction
06/02/2005US20050119219 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
06/02/2005US20050119213 Vascular therapeutics
06/02/2005US20050119201 Inhibitor of dna methylation
06/02/2005US20050119198 Novel target to inhibit angiogenesis
06/02/2005US20050119190 Anticoagulants; cardiovascular disorders; thrombosis
06/02/2005US20050119173 Novel potassium-dependent sodium-calcium exchanger
06/02/2005US20050119162 Anxiolytic agents; using transferrins; quality of life for cancer patients; antiarthritic agents; antiinflammatory agents; compaction; uniform particle size
06/02/2005US20050119159 Remedy for ischemic heart failure
06/02/2005US20050118715 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
06/02/2005US20050118696 Methods and means for modulating PGE synthase activity
06/02/2005US20050118638 Using thyrotrophin (TSH) receptor as diagnostic tool in detection of autoimmune diseases; competive binding assay
06/02/2005US20050118585 Using allelic variation in bone morphogenic signaling family proteins as diagnostic tool in detection of vision defcets
06/02/2005US20050118579 Using allelic variation in canalicular multispecific organic anion transporter (cMOAT) gene as diagnostic tool in detection of liver and bile duct disorders
06/02/2005US20050118562 Methods for minimizing spasticity in blood vessel grafts
06/02/2005US20050118288 Method for producing high-quality hydropbic licorice extract
06/02/2005US20050118263 Composition
06/02/2005US20050118192 Viral preparations, vectors, immunogens, and vaccines
06/02/2005CA2545802A1 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
06/02/2005CA2544230A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic
06/01/2005EP1536010A1 Preventives/remedies for cancer
06/01/2005EP1536000A1 Method of judging inflammatory disease
06/01/2005EP1535922A1 Pyrrolopyridine derivative and use thereof
06/01/2005EP1535920A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
06/01/2005EP1535919A2 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
06/01/2005EP1535915A1 Furan or thiophene derivative and medicinal use thereof
06/01/2005EP1535913A1 Novel quaternary ammonium compounds
06/01/2005EP1535911A1 Metabolically inert anti-inflammatory and anti-tumor antifolates
06/01/2005EP1535910A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
06/01/2005EP1535909A2 Cyclic amine derivatives and their use as drugs
06/01/2005EP1535907A1 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
06/01/2005EP1535906A1 Nitrogen-containing compounds
06/01/2005EP1535891A1 Remedy
06/01/2005EP1535630A1 Preventive for the onset of diabetes
06/01/2005EP1535629A1 Drugs for improving the prognosis of brain injury and a method of screening the same
06/01/2005EP1535624A1 Chronic myeloid leukemia (cml) therapy
06/01/2005EP1535609A1 Nf-kb activation inhibitors
06/01/2005EP1535512A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF
06/01/2005EP1535067A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
06/01/2005EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
06/01/2005EP1534736A2 Nogo receptor antagonists
06/01/2005EP1534725A2 Compounds and methods for inhibiting selectin-mediated function
06/01/2005EP1534717A1 Beta-lactamase inhibitor prodrug
06/01/2005EP1534707A1 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
06/01/2005EP1534706A1 Furanthiazole derivatives as heparanase inhibitors
06/01/2005EP1534703A2 Antagonists of melanin concentrating hormone receptor
06/01/2005EP1534695A2 Tyrosine kinase inhibitors
06/01/2005EP1534693A2 1, 3-diamino-2-hydroxypropane prodrug derivatives
06/01/2005EP1534687A1 Pyrimidine compounds
06/01/2005EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
06/01/2005EP1534676A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
06/01/2005EP1534674A2 Cytotoxic agents containing novel potent taxanes and their therapeutic use
06/01/2005EP1534668A1 Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
06/01/2005EP1534667A1 Muscarinic agonists
06/01/2005EP1534658A2 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
06/01/2005EP1534391A1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
06/01/2005EP1534390A2 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
06/01/2005EP1534389A2 Pyrazolopyrimidines as kinase inhibitors
06/01/2005EP1534367A1 Medicament dispenser
06/01/2005EP1534346A2 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
06/01/2005EP1534345A2 Method and device for inducing biological processes by micro-organs
06/01/2005EP1534332A2 Antibodies and uses thereof
06/01/2005EP1534331A2 Membrane associated tumor endothelium markers
06/01/2005EP1534300A2 3, 10, and 12a substituted tetracycline compounds
06/01/2005EP1534296A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
06/01/2005EP1534293A1 Anti-inflammatory compositions and methods of use
06/01/2005EP1534290A2 Novel inhibitors of kinases
06/01/2005EP1534289A1 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
06/01/2005EP1534282A2 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
06/01/2005EP1534281A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace)
06/01/2005EP1534278A2 Nitrosated proton pump inhibitors, compositions and methods of use
06/01/2005EP1534275A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
06/01/2005EP1534272A2 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors
06/01/2005EP1534271A1 Antitumor compound and therapeutic uses thereof
06/01/2005EP1534269A1 Oxime conjugates and methods for their formation and use
06/01/2005EP1534267A1 Pyrrolidine derivatives as tryptase inhibitors
06/01/2005EP1534265A1 Combination of an aromatase inhibitor with a bisphosphonate
06/01/2005EP1534264A2 Compounds that modulate the activity of ptp-1b and tc-ptp
06/01/2005EP1534263A2 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
06/01/2005EP1534261A2 Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
1 ... 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 ... 1564